Últimas noticias sobre Pharma Mar (OTC:PHMMF) Bolsa

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Pharma Mar SA

WIIM

FB Financial shares are trading higher. The stock may also be moving on continued strength following a better-than-expected Q3 earnings report yesterday. Also, Keefe, Bruyette & Woods raised its price target on the stock from $48 to $50.

Data analysis suggests that a single entity may be behind a massive $26 million bet on Donald Trump <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41303762/trumps-election-odds-on-polymarket-gary-genslers-doubts-about-cryptocurrencys-future-shiba">winning the election</a> on the Polymarket platform.
What Happened: According to a detailed <a href="https://x.com/fozzydiablo/status/1846369866091319743">thread</a> by X user Fozzy Diablo on Wednesday, four accounts &#8211; Fredi9999, PrincessCaro, Michie, and Theo4 &#8211; have been observed making substantial bets on Trump-related outcomes.
The betting patterns of these accounts show striking similarities, with one account typically taking over when another stops, suggesting coordinated activity.
Fozzy Diablo notes, &#8220;There is very little overlap within each account, suggesting they are all the same entity.&#8221;
The deposit patterns for these accounts are remarkably similar, further supporting this theory. Fozzy Diablo reports, &#8220;All flow comes from Kraken in the form of $500,000 or $1 million deposits.&#8221;
The motivation behind this substantial investment remains unclear. Fozzy Diablo speculates, &#8220;Is the end goal a simple double up? Or is $26 million a cheap way to sway the public opinion in favor of Trump weeks before the election?&#8221;
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Why It Matters: This unusual betting activity raises questions about the potential manipulation of prediction markets and their influence on public opinion. While prediction markets are often viewed as indicators of public sentiment, this case highlights the possibility of large-scale interventions skewing the perceived odds.
The implications of such a significant bet go beyond mere financial speculation. As Fozzy Diablo points out, &#8220;To me there is clearly another play here, I would think there are better proxy bets if you are in favor of Trump. Only way I can see it as a hedge would be if all of this was pro Kamala.&#8221;
The user Fredi9999 was already flagged by veteran Polymarket traders on Oct.7 for their heavy Trump-related activity. Polymarket trader Domer noted that Fredi9999 has a remarkable similarity to Elon Musk in being <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41214859/this-polymarket-trader-holds-6-4-million-in-donald-trump-election-bets-if-not-musk-definit">wealthy and tech-savvy</a>.
What&#8217;s Next: The fallout of the election for the crypto industry will take center stage at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41341588/donald-trumps-world-liberty-financial-token-sales-hit-220m-in-first-hour-website-faces-mul">Donald Trump&#8217;s World Liberty Financial Token Sales Hit $220M In First Hour, Website Faces Multiple Outages</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$26M Bet On Trump's Election Victory Fuels Speculation Of Coordinated Activity On Polymarket

Trading Ideas

Universe Pharmaceuticals Shares Halted; Up 11.80%

Blackberry Shares Resume Trade

Crypto analyst Murad Mahmudov's recent tweet outlined his strategy for identifying potential winners in what he calls the upcoming <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41214724/memecoin-supercycle-means-best-tokens-are-cults-says-analyst-do-dogecoin-and-shiba-inu-fit">&#8220;Memecoin Supercycle&#8221; of 2025.</a>
What Happened: Mahmudov&#8217;s advice focuses on a multi-faceted approach to selecting meme coins with high growth potential. He suggests investors should "Buy Memecoins that can become very big" and "Buy coins that have undergone multiple -70%" drops, indicating a belief in the potential for significant rebounds.
The analyst emphasizes the importance of studying coins with specific characteristics. He advises looking at tokens that have spent "a long time under $10 million" market capitalization and those "which have people hustling for free," suggesting that community engagement and grassroots support could be key indicators of future success.
Mahmudov also <a href="https://x.com/MustStopMurad/status/1846265044201263517">recommends</a> using analytical tools like BubbleMaps and HolderScan to examine token distribution, highlighting the importance of understanding ownership patterns in potential investments.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Mahmudov's Picks: In another <a href="https://x.com/MustStopMurad/status/1846337975686168647">tweet</a>, Mahmudov lists several specific tokens he believes could be &#8220;Giant 2025 Winners,&#8221; including Gigachad (CRYPTO: GIGA), Mog Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MOG</a>), Apu Apustaja (CRYPTO: APU), Popcat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>), and Lock In (CRYPTO: LOCKIN), among others.
He also includes HarryPotterObamaSonic10Inu (CRYPTO: BITCOIN) in this list, suggesting he sees potential for the leading cryptocurrency alongside these smaller, more speculative assets.
While Mahmudov&#8217;s advice may appeal to risk-tolerant investors seeking high-reward opportunities, it&#8217;s important to note that investing in meme coins carries significant risks. The volatile nature of these assets, combined with their often-limited utility and speculative value, means that losses can be substantial.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41341588/donald-trumps-world-liberty-financial-token-sales-hit-220m-in-first-hour-website-faces-mul">Donald Trump&#8217;s World Liberty Financial Token Sales Hit $220M In First Hour, Website Faces Multiple Outages</a></li>
</ul>

$MOG

$POPCAT

'Memecoin Supercycle' Trader Shares 5 Tips, Reveals 'Giant 2025 Winners' List That Skips Dogecoin, Shiba Inu For Newer Memes

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Wednesday.
The Dow traded up 0.59% to 42,994.38 while the NASDAQ fell 0.05% to 18,306.79. The S&amp;P 500 also rose, gaining, 0.19% to 5,826.42.
Check This Out: <a href="https://www.benzinga.com/markets/24/10/41342689/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a>
Leading and Lagging Sectors Utilities shares jumped by 0.8% on Tuesday.
In trading on Tuesday, consumer staples shares fell by 0.5%.
Top Headline
U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) posted better-than-expected quarterly earnings on Wednesday.
The company reported third-quarter adjusted earnings per share of $1.03, beating the analyst consensus estimate of 99 cents. Quarterly revenues of $6.864 billion missed the analyst consensus estimate of $6.895 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>180 Life Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares shot up 713% to $12.36. 180 Life Sciences interim CEO said that the company is planning to enter the online gaming industry with its newly acquired gaming technology platform.</li>
<li>Shares of Altus Power, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) got a boost, surging 15% to $3.48 after the company announced that a formal review of strategic alternatives has been underway by its Board of Directors. Also, the company reaffirmed its FY24 guidance.</li>
<li>Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>) shares were also up, gaining 399% to $5.64 after the company announced a $2.5 million investment and licensing agreement with ASPIS.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Bright Minds Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) shares dropped 37% to $24.24. Firefly Neuroscience collaborated with Bright Minds Biosciences to analyze the data from its positive Phase 1 study using its Artificial Intelligence.</li>
<li>Shares of Silvaco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) were down 25% to $8.34 after the company reported a decline in orders from Asia during third quarter and cut its FY24 revenue outlook.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) was down, falling 17% to $10.45 after the FDA placed a clinical hold on the company&#8217;s investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $70.46 while gold traded up 0.6% at $2,694.90.
Silver traded up 1.6% to $32.270 on Wednesday, while copper rose 1% to $4.3810.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.02%, Germany's DAX gained 0.1% and France's CAC 40 fell 0.17%. Spain's IBEX 35 Index rose 0.75%, while London's FTSE 100 gained 1.15%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 1.83%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index gaining 0.05% and India's BSE Sensex falling 0.39%.
Economics
<ul>
<li>U.S. mortgage applications fell by 17% from the previous week during the second week of October.</li>
<li>Export prices in the U.S. declined by 0.7% month-over-month in September, exceeding market estimates of a 0.4% fall.</li>
<li>Import prices declined by 0.4% from the previous month in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca"> Jim Cramer: &#8216;We Need More Uranium,&#8217; Recommends This Stock; Says Novo Nordisk &#8216;Doesn&#8217;t Hold A Candle&#8217; To Big Pharma Riva</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca">l</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Markets

AMPS

ATNF

DRUG

NVAX

SVCO

Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views

ASML

Live On CNBC; Steve Weiss Sells ASML

JP Morgan analyst Domingos Falavina maintains XP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) with a Overweight and raises the price target from $28 to $29.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on XP, Raises Price Target to $29

The Bear Cave&#8217;s Edwin Dorsey has publicly accused short seller Hindenburg Research of plagiarism on the heels of both firms targeting <a href="https://www.benzinga.com/news/24/10/41170031/short-seller-alleges-roblox-facilitated-widespread-child-abuse-potentially-played-a-role-in-mass-sho">video game stock Roblox</a>.
What To Know: Dorsey publishes bearish reports on public companies through The Bear Cave newsletter, which is popular among short sellers. Dorsey <a href="https://x.com/StockJabber/status/1844725136265765229">says</a> he doesn&#8217;t short the companies he publishes on.
On Tuesday, Dorsey published a report titled &#8220;Problems at Hindenburg Research,&#8221; accusing Hindenburg&#8217;s Nate Anderson of not properly acknowledging that the short seller uses information from The Bear Cave for its reports. 
Dorsey said Anderson has failed to cite The Bear Cave in its own reports multiple times, most recently in the firm&#8217;s <a href="https://www.benzinga.com/news/24/10/41230411/short-seller-hindenburg-issues-report-on-roblox-accuses-company-of-misleading-metrics">coverage</a> of Roblox Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>).
&#8220;At times, Hindenburg used virtually identical reporting, wording, sourcing, and research methods in its Roblox report yet doesn't mention The Bear Cave once in its 16,405-word report,&#8221; Dorsey said.
See Also: <a href="https://www.benzinga.com/general/gaming/24/10/41255828/roblox-denies-hindenburgs-accusations-of-inflating-metrics-failing-at-child-safety-calls-them-misl">Roblox Denies Hindenburg&#8217;s Accusations Of Inflating Metrics, Failing At Child Safety — Calls Them &#8216;Misleading&#8217;</a>
Dorsey went on to highlight several instances in which Hindenburg published similar research on companies after The Bear Cave. He repeatedly took issue with similar wording, and even highlighted the use of identical company descriptions related to Axos Financial. 
Anderson posted a <a href="https://x.com/NateHindenburg/status/1846206172354765189">response</a> to Dorsey&#8217;s report on X this week, stating that the report &#8220;falsely and ridiculously alleged&#8221; Hindenburg plagiarized his work. Anderson said he doesn&#8217;t read Dorsey&#8217;s blog and has never used any of his work for Hindenburg research.
Interestingly enough, Anderson said he spoke with Dorsey on the phone last week before Dorsey published his report alleging plagiarism by Hindenburg.
&#8220;He could easily see the evidence for himself in front of him. He acknowledged this when we spoke, but instead, decided to ignore it and shamelessly lob false allegations of plagiarism anyway,&#8221; Anderson said. 
He shared a <a href="https://x.com/NateHindenburg/status/1846207394457493724">screenshot</a> of a deleted tweet from Dorsey last week in which Dorsey confirms the call with Anderson and refers to him as a &#8220;good guy&#8221; before saying, &#8221; I don&#8217;t think there was any bad intent here.&#8221;
An X user asked Dorsey why he deleted the tweet. Dorsey <a href="https://x.com/StockJabber/status/1846242373631893836">said</a>, &#8220;I slept on it and then realized there were a lot more issues than originally discussed I also felt like the call was not entirely truthful as I evaluated more information.&#8221;
Dorsey <a href="https://x.com/StockJabber/status/1846240710204576169">responded</a> to Anderson&#8217;s X post Tuesday afternoon, further accusing Anderson of improper disclosure and claiming he made false allegations in his post defending Hindenburg&#8217;s reporting practices. Still, the response was largely focused on The Bear Cave getting the credit Dorsey believes it deserves.
&#8220;We can have different views on the right approach, but that in no way means you can't or shouldn't cite The Bear Cave when appropriate,&#8221; Dorsey said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41335977/3-stocks-targeted-by-short-sellers-making-strong-recoveries">3 Stocks Targeted by Short Sellers Making Strong Recoveries</a></li>
</ul>
Illustration created using artificial intelligence via MidJourney.

Short Sellers

RBLX

Short Seller Showdown: The Bear Cave Accuses Hindenburg Of Plagiarism

EPAC

Enerpac Tool Group shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $26.

HUTCHMED shares are trading higher after the company announced high-level results from the SAVANNAH Phase II trial.

JP Morgan analyst Christopher Horvers maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Neutral and raises the price target from $260 to $290.

TSCO

JP Morgan Maintains Neutral on Tractor Supply, Raises Price Target to $290

Shannon O&#8217;Brien, the former chair of the Cannabis Control Commission of Massachusetts lost her legal battle with State Treasurer Deborah Goldberg resulting in O&#8217;Brien <a href="https://www.benzinga.com/markets/cannabis/24/09/40797285/massachusetts-cannabis-chief-shannon-obrien-loses-job-after-year-long-suspension-and-costly-lega">being fired last month.</a>
Goldberg, who <a href="https://masscannabiscontrol.com/2024/09/cannabis-control-commissioner-bruce-stebbins-named-acting-chair-by-state-treasurer-deborah-b-goldberg/">named</a> Bruce Stebbins acting chair of the regulatory body, expressed concern about attracting strong candidates while state lawmakers consider changes to the oversight of the struggling agency, <a href="https://commonwealthbeacon.org/marijuana/search-for-new-cannabis-agency-chair-could-be-hampered-by-legislatures-review-goldberg-says/">reported</a> CommonWealth Beacon.
"We've made a commitment to begin looking. It might prove to be more challenging because those who might consider it [the state Legislature] might be concerned about changes that could take place," Goldberg told reporters following her address to the Greater Boston Chamber of Commerce.
<h2 class="wp-block-heading">&#8216;Unclear And Self-Contradictory&#8217;</h2>
On October 30, state lawmakers will hold a hearing to review the organizational structure of the commission. This follows a letter from the state inspector general addressed to Senate President Karen Spilka and House Speaker Ron Mariano, among others, which described the commission&#8217;s enabling statute as &#8220;unclear and self-contradictory&#8221; regarding the oversight roles within the agency.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Under the 2016 voters-approved measure to legalize recreational marijuana, cannabis shops are regulated similarly to liquor stores, which are overseen by the Alcoholic Beverages Control Commission (ABCC) within the state treasurer&#8217;s office. However, following lawmakers' amendments to the voter-approved law, Goldberg&#8217;s authority was reduced, while proposing the commission's structure to resemble the five-member Gaming Commission.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/38803976/marthas-vineyard-has-a-cannabis-crisis-medical-recreational-users-could-run-out-of-access-by-fal">Martha&#8217;s Vineyard Has A Cannabis Crisis: Medical, Recreational Users Could Run Out Of Access By Fall As Island&#8217;s Sole Producer Will Close Soon</a>
Goldberg didn't weigh in on whether the legislative rewrite was a mistake. She said the cannabis industry is "so new" adding that "every state has had its own set of glitches."
<h3 class="wp-block-heading">Background</h3>
O'Brien was originally appointed to <a href="https://www.benzinga.com/markets/cannabis/22/09/28750893/ma-cannabis-regulator-gets-new-chair-other-marijuana-key-executive-changes-you-should-know-about">serve a five-year term in 2022</a> and has denied the misconduct allegations. Goldberg suspended O'Brien in September 2024 accusing her of making "racially, ethnically and culturally insensitive statements."
"The Chair [O&#8217;Brien] committed gross misconduct and demonstrated she is unable to discharge the powers and duties of a CCC commissioner," Goldberg said in a statement. "I do so with deep regret because she has a long history of public service, and when appointed I anticipated she would lead the Commission capably and in an appropriate manner."
Goldberg's decision to fire O&#8217;Brien followed over twenty hours of meetings and an evaluation of testimonies, case law, and policies. O'Brien spent close to $750,000 in taxpayer dollars on legal fees, engaged lawyers to contest her suspension through court battles and at least four confidential <a href="https://www.benzinga.com/markets/cannabis/24/09/40754893/leadership-shake-ups-in-cannabis-and-psychedelics-marylands-cannabis-chief-resigns-costly-legal-">hearings that concluded in early July.</a>
O&#8217;Brien now plans to appeal her firing to the Supreme Judicial Court.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/22/09/29072315/credibility-at-stake-this-cannabis-control-chair-has-interests-in-two-marijuana-projects-before-">Credibility At Stake? Cannabis Control Chair Has Interest In Two Marijuana Projects Before Her Board</a></li>
</ul>

Cannabis

Regulations

Politics

Former Cannabis Comish Firing Sparks Debate On Oversight In Massachusetts: What's Next For The Industry?

ASPN

Aspen Aerogels shares are trading higher after the company announced it won a conditional commitment for a proposed DOE loan worth up to $670.6 million. Also,  the company said it expects its second plant to provide between $1.2 to $1.6 billion in revenue.

JP Morgan analyst David Karnovsky maintains Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) with a Overweight and raises the price target from $118 to $119.

JP Morgan Maintains Overweight on Omnicom Group, Raises Price Target to $119

Vice President <a href="https://www.benzinga.com/topic/kamala-harris">Kamala Harris,</a> in an interview Tuesday with Charlamagne Tha God on &#8220;The Breakfast Club,&#8221; agreed with her host who referred to former President <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a> as a fascist.
The conversation touched on key issues concerning Black Americans such as loans for Black entrepreneurs, cannabis legalization and health issues. Harris also contrasted her vision to Trump's. But then Charlamagne jumped in: "The other is about fascism. Why can't we just say it?" 
Harris responded, "Yes, we can say that."
Harris&#8217;s Tuesday appearance on the popular Detroit-based hip-hop radio show was part of a larger effort to <a href="https://www.benzinga.com/markets/cannabis/24/10/41314909/kamala-harris-unveils-policy-plan-for-black-men-focusing-on-economic-opportunity-health-cannabis">shore up support among Black men,</a> whose enthusiasm for the Democratic ticket has waned.
<h2 class="wp-block-heading">Cannabis Legalization, Tight Race</h2>
Regarding cannabis legalization, Harris reiterated a <a href="https://www.benzinga.com/markets/cannabis/24/09/41106120/kamala-harris-we-need-to-legalize-cannabis-vp-says-for-first-time-as-presidential-candidate-in-a">comment she made</a> on the basketball-focused podcast "All the Smoke," implying that Black men in particular have been overly criminalized for cannabis possession. 
"I know exactly how those laws have been used to disproportionally impact certain populations and specifically Black men," she told Charlamagne.
Harris acknowledged that the presidential race is tight but sounded positive. "This is a margin-of-error race," she said. "I'm going to win, but it's tight."
Read Also: <a href="https://www.benzinga.com/news/24/10/41348386/trump-falls-3-points-behind-harris-in-new-poll-economic-worries-dominate-voter-concerns-report">Trump Falls 3 Points Behind Harris In New Poll, Economic Worries Dominate Voter Concerns: Report</a>
<h2 class="wp-block-heading">Trump: Weak, Dangerous, Admires Dictators</h2>
Harris described Trump as "weak" although dangerous. She accused him of enabling policies that harm working Americans while undermining democracy, saying he would make it "more difficult for working people to get by and to destroy our democracy."
She also blasted the former president&#8217;s admiration for authoritarian leaders such as Vladimir Putin, bringing up a report that Trump provided Russia with Covid-19 testing kits during the pandemic while Black Americans were disproportionately dying. 
"The man is really quite weak," Harris said. "It's a sign of weakness that you want to please dictators and seek their flattery and favor."
Charlamagne asked whether the Justice Department is moving too slowly to prosecute Trump's involvement in <a href="https://www.benzinga.com/government/21/01/19049660/washington-dc-descends-into-anarchy-as-trump-supporters-storm-us-capitol-delay-electoral-college-vot">the Jan. 6 capitol riots</a> and whether he should be in jail rather than running for president. Harris reiterated her condemnation of the capitol riots but skirted the slow pace of the Justice Department's prosecution.
"The court should handle that, and I'm going to handle November," Harris said.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41314909/kamala-harris-unveils-policy-plan-for-black-men-focusing-on-economic-opportunity-health-cannabis">Kamala Harris Unveils Policy Plan For Black Men, Focusing On Economic Opportunity, Health, Cannabis Legalization</a></li>
</ul>
Photo: Shutterstock

Government

Legal

Kamala Harris Agrees Trump Is A Fascist In Interview With Charlamagne Tha God: 'Yes, We Can Say That'

JP Morgan analyst Christopher Horvers maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Overweight and raises the price target from $1125 to $1300.

ORLY

JP Morgan Maintains Overweight on O'Reilly Automotive, Raises Price Target to $1300

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported on Tuesday <a href="https://www.benzinga.com/news/earnings/24/10/41328272/unitedhealth-q3-earnings-revenue-and-eps-beat-revises-annual-profit-guidance-as-change-healthcare-c">upbeat earnings for its third quarter</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<h1 class="wp-block-heading">RBC Capital Markets On UnitedHealth Group</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/621e2beb6dd755000146b9d3/ben-hendrix">Analyst Ben Hendrix</a> reiterated an Outperform rating while reducing the price target from $615 to $595.
UnitedHealth reported its third-quarter adjusted earnings at $7.15 per share, beating the consensus of $7, "reflecting broad-based growth in consumers served and operating efficiency gains," Hendrix wrote in a note. The gains were partially offset by medical costs that exceeded expectations by around 80 basis points (bps), he added.
Among the reasons for higher-than-anticipated medical costs, management cited "a ~20% upshift in Medicare coding intensity among certain hospital systems," the analyst stated. He lowered the earnings estimate for 2025 from $30.84 per share to $29.75 per share.
<h1 class="wp-block-heading">Stephens On UnitedHealth Group</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/583f1c0caae83900016b3ad5/scott-fidel">Analyst Scott Fidel</a> maintained an Overweight rating while cutting the price target from $632 to $605.
Management suggested the adjusted earnings in 2025 could be at the high end of the initial guidance, which likely matches $30 per share, Fidel said. Although this is 8.6% higher than the midpoint of the 2024 guidance, it is below the Street&#8217;s projection of $31.17 per share, he added.
"UNH hopes to initiate guidance with the capacity to drive positive revisions throughout 2025. UNH emphasized 3Q24 pressure points pertaining to the Medicaid redeterminations-driven rate/acuity mismatch, higher-than-expected hospital coding intensity in MA, and pull forward impacts from the IRA resulting in accelerated specialty Rx trends," the analyst wrote.
<h1 class="wp-block-heading">Cantor Fitzgerald On UnitedHealth Group</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b6cbc2b85e9300014425b6/sarah-james">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b6cbc2b85e9300014425b6/sarah-james">Sarah James</a> reaffirmed an Overweight rating while slashing the price target from $644 to $591.
"We are walking away from 3Q24 earnings with the sentiment that the vast majority of the unknowns have been cleared up," James wrote in a note.
The Medical Loss Ratio (MLR) was worse than expected and this could escalate in the fourth quarter, the analyst stated. The stock sell-off post UnitedHealth's earnings release appears "overdone" and presents an opportunity to buy, she added.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Truist Securities On UnitedHealth Group</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c2a8e2b85e930001ba538c/david-macdonald">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c2a8e2b85e930001ba538c/david-macdonald">David MacDonald</a> reiterated a Buy rating while reducing the price target from $640 to $625.
UnitedHealth reported mixed results for the third quarter, with adjusted earnings topping consensus expectations, despite MLR coming in at 85.2%, worse than consensus of 84.4%, MacDonald said. The company tightened its fiscal 2024 guidance to $27.50-$27.75 per share, versus the prior $27.50-$28.00 per share, he added.
The higher-than-expected MLR was due to "a handful of lingering pressures (increase in hospital coding intensity, Medicaid rate/acuity mismatches tied to the wind-down of redeterminations) mentioned in 2Q," the analyst stated. The company provided conservative initial guidance for 2025 due to "the fluid environment," he further wrote.
<h1 class="wp-block-heading">KeyBanc Capital Markets On UnitedHealth Group</h1>
Analyst Matthew Gillmor maintained an Overweight rating while cutting the price target from $675 to $650.
UnitedHealth's third-quarter results were "disappointing, primarily highlighted by higher medical costs and an initial EPS outlook for 2025 that was below expectations," Gilmor said.
There had been optimism around the company being able to accelerate earnings growth in 2025 to the long-term targets, the analyst stated. "However, ongoing headwinds (mostly MA related), along with UNH&#8217;s decision to maintain organic investments, likely push out this thesis until 2026," he added.
<h1 class="wp-block-heading">Oppenheimer On UnitedHealth Group</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584847d8ee7bf6000154d222/michael-wiederhorn">Analyst Michael Wiederhorn</a> reaffirmed an Outperform rating and price target of $610.
UnitedHealth's MCR missed expectations by around 100 bps due to persistent hospital coding pressure, continued Medicaid rate/acuity mismatches, and higher drug costs, Wiederhorn said. "Some extreme hospitals are upcoding up 20%+," he added.
"UNH is seeing elevated utilization of high-cost-specialty prescriptions (auto-immune, cancer, cardio) as beneficiaries take advantage of the 2024 changes from the Inflation Reduction Act (IRA) at a greater rate than UNH expected," the analyst wrote. "However, management feels appropriately priced for 2025 (bids submitted in June) when the 2025 IRA changes more significantly shift the cost burden onto plans, with higher upfront premiums," he further stated.
UNH Price Action: Shares of UnitedHealth Group had risen by 3.29% to $574.40 at the time of publication on Wednesday.
Read More: • <a href="https://www.benzinga.com/news/24/10/41338000/why-cvs-health-stock-is-trading-lower">Why CVS Health Stock Is Trading Lower</a>
Photo: JHVEPhoto/Shutterstock.com

Analyst Color

Earnings Beats

Health Care

Reiteration

Movers

Why 5 Of 6 UnitedHealth Analysts Are Cutting Forecasts After Q3 Earnings Release

JP Morgan analyst Andrea Teixeira maintains Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) with a Overweight and raises the price target from $38 to $41.

JP Morgan Maintains Overweight on Keurig Dr Pepper, Raises Price Target to $41

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar SA has reported on its share buyback operations conducted from July 29 to August 2, 2024,...

Pharma Mar SA Executes Share Buyback Program

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar S.A. has actively executed its share buy-back program, as detailed in a recent report cov...

Pharma Mar Executes Strategic Share Buy-Backs

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar SA has actively executed its share buyback program from August 12 to August 16, 2024, pur...

Pharma Mar SA Continues Share Buyback Program

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar SA has reported transactions under its share buy-back program, executed between August 19...

Pharma Mar SA Executes Share Buy-Back

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar SA has reported on share buyback transactions executed from August 26 to August 30, 2024,...

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar SA has reported on its recent share buyback transactions, which took place from September...

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar SA has actively pursued its share buyback program, acquiring shares on the BME over multi...

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar SA has actively executed its share buyback program, purchasing shares at progressively hi...

Pharma Mar SA Executes Progressive Share Buyback

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar S.A. has successfully completed its share buyback program ahead of schedule, reaching the...

Pharma Mar Concludes Buyback Program Early

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar and Jazz Pharmaceuticals have announced promising phase III trial results for their drug ...

Comments

Pharma Mar

Noticias

Últimas noticias sobre Pharma Mar (OTC:PHMMF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL